Elicio signals delay in mid-stage cancer vaccine study; shares slump

Elicio Therapeutics

31/03/2025 18:25

** Biotech firm Elicio Therapeutics' ELTX.O shares fall 14% to an over 2-month low of $6.71

 ** ELTX now expects mid-stage study data of its lead experimental vaccine, ELI-002, in Q3 2025 vs. previous expectation of H1 2025

** Co is testing vaccine against certain types of solid tumors that are caused by mutations in the KRAS gene, which are common in pancreatic, colorectal, and non-small cell lung cancers

** ELTX's net loss also widens in 2024 compared with 2023

** As of last close, ELTX has risen 2.5% in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))